Membership

IHE  The Swedish Institute for Health Economics

The Swedish Institute for Health Economics, IHE, is a well-established, independent health economic research institute that provides high-quality research and expert consultation in the field of health care. We have ongoing projects with over 50 customers worldwide representing national authorities, pharmaceutical companies, healthcare providers, industry associations, and patient groups.

IHE was founded in 1979 as the first health economic research center in Sweden and is one of the oldest health economic research centers in Europe.

In addition to the head office in Lund, IHE also has an office in central Stockholm.

IHE is home to over 30 highly qualified, multidisciplinary specialists in health economics, medical sciences and statistics. This makes IHE one of Sweden’s largest teams of health economists. IHE has close collaborations with academia, and several employees also work part-time at Lund University or Karolinska Institutet.

SGS Clinical Research

SGS Pharma Clinical Research is a leading CRO specializing in early-stage development and functional biometrics (Phases I–IV). With a strong presence in Europe and the Americas, SGS offers a comprehensive range of clinical trial services, including full early-phase drug development consultancy, clinical project management and monitoring, biometrics, as well as medical safety and regulatory services. SGS operates its own clinical pharmacology unit in Belgium featuring a viral challenge testing facility and a phase I patient unit based in Hungary. SGS has a wealth of expertise in FIH studies, viral challenge testing, biosimilars and complex PK/PD studies with a strong therapeutic focus on Infectious Diseases, Vaccines, Respiratory, Dermatology and Oncology.

Precision for Medicine

Enriching the latest science, technology and data to conquer the complexity of developing novel therapies.

We’ve all known patients facing critical illnesses. Your work may one day provide hope to those patients. Bringing that day forward is why Precision for Medicine exists. We are the first global, precision medicine clinical research organization. We incorporate laboratory expertise, clinical trial excellence, and data intelligence to deliver critical insights into patient biology.

MedChemExpress

MedChemExpress (MCE) is a leading global supplier of life science research products and services, dedicated to accelerating scientific research and drug development. We provide a comprehensive portfolio of high-quality products, including inhibitors, diverse compound libraries, recombinant proteins, and antibodies. In addition, our experienced scientific team offers an end-to-end service system covering drug discovery screening, custom synthesis, data analysis, and bioactivity evaluation. Backed by stringent quality control standards, MCE serves more than 15,000 research institutions worldwide as a trusted partner in research innovation.

Apriligen

Apriligen’s mission is to cure rare, monogenic pediatric diseases. Our first clinical gene therapy program, APR-2020, is a purpose-built lentiviral vector to treat RPS19 deficient Diamond Blackfan Anemia (“DBA”).

Parexel

Parexel is a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart®. We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for Innovative Approaches to Patient-Centric Research and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships. For more information, visit parexel.com and follow us on LinkedIn, X, Facebook and Instagram.  

Syntagon Denmark

Founded in 1998 in Södertälje, Sweden, Syntagon has more than two decades of experience in developing and manufacturing complex drug substances.

As an independent Swedish CDMO, we build on a long legacy of scientific excellence rooted in the strong life science tradition of Sweden. From world‑leading pharmaceutical innovation to pioneering chemical development, the region has fostered a culture of precision, responsibility, and deep scientific curiosity. This heritage continues to shape how we work and how we partner with customers around the world.

With a proven track record in API development, GMP manufacturing, and advanced analytical and purification technologies, Syntagon delivers fit‑for‑purpose solutions from early development to commercial supply. Our expertise spans small molecules, novel excipients, drug conjugates, and peptide conjugates, enabling us to support both innovative pipelines and established programs with the same level of scientific rigor.

What defines us is our commitment—to science, to quality, and to the people who rely on the medicines we help bring forward. We believe in collaboration, transparency, and building long‑term relationships founded on trust. At Syntagon, your molecule is met with the same dedication, care, and craftsmanship that have guided us since 1998.

Syntagon. Swedish science, global impact.

Ramskov Consulting Group

We are life science consultants.

Our core capabilities are in the field of optimizing and expanding value chains, leading strategic initiatives, and driving digital transformations for our clients.

We aspire to be trusted advisors and have a reputation of being really cool and easy to work with.

Apeloa

Apeloa, founded in 1989, is a publicly traded company as part of the Hengdian Group. Headquartered in Hengdian, Zhejiang, Apeloa has over 7,000 employees worldwide. Apeloa is China’s top 2 exporter of APIs and the top 5 CDMO companies. It also ranks 36th among China’s pharmaceutical companies. Apeloa’s core businesses include API, CDMO, FDF, and ACI, with seven API manufacturing sites (five chemical synthesis and two fermentation) and two drug product sites. Our products cover cardiovascular, anti-infection, psychotropic, and anti-cancer treatments, with production bases in Zhejiang, Shandong, and Anhui. Since 2007, our main API manufacturing sites have passed audits by NMPA, US FDA, EMEA, and PMDA, establishing us as a leading API enterprise. Our CDMO business maintains strategic partnerships with top pharmaceutical companies globally, offering comprehensive services and sustaining high growth. Apeloa’s brands, “Baishixin” and “Tianliwei,” have been widely recognized, and our first extended-release product has successfully entered the U.S. market. Apeloa implements the development strategy of “Global API Leader, CDMO Excellence, High-quality & Affordable Medicine, Expanding Aesthetic & Care Ingredients”, with annual R&D expenses exceeding 5% of revenue. We support leading technology platforms with over 1,300 scientists and collaborations with top universities. Our philosophy emphasizes technology driven, high-standard compliance, and cost efficiency, aiming to be a global leading technology-driven pharmaceutical manufacturer solutions provider.

KBI Biopharma

As the icon of next-generation CDMOs, KBI Biopharma is driving breakthroughs in biopharmaceutical development and manufacturing that positively impact the lives of patients worldwide.